Antimicrobial susceptibility of Brucella melitensis isolates in Peru

Ryan C Maves1, Rosa Castillo, Alfredo Guillen

  • 1Division of Infectious Diseases, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, USA. Ryan.Maves@med.navy.mil

Insights

Brucellosis treatment in Peru showed all tested bacteria were sensitive to common antibiotics. This suggests drug resistance is not a primary cause of patient relapses in this region.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Brucellosis poses a significant public health challenge in Peru.
  • Brucella melitensis biotype 1 is a common cause of human brucellosis.

Purpose of the Study:

  • To evaluate the antimicrobial susceptibility of Brucella melitensis biotype 1 strains isolated from human cases in Peru.
  • To investigate the potential relationship between antimicrobial resistance and brucellosis relapses.

Main Methods:

  • Antimicrobial susceptibility testing was performed using the Etest method.
  • Minimum Inhibitory Concentrations (MICs) were determined for doxycycline, azithromycin, gentamicin, rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
  • 48 human Brucella melitensis biotype 1 isolates from Peru (2000-2006) were analyzed.

Main Results:

  • All 48 evaluated Brucella melitensis isolates were sensitive to the tested antibiotics.
  • No drug resistance was observed in the isolates during the study period.
  • Brucellosis relapses were not found to be associated with antimicrobial resistance.

Conclusions:

  • The tested Brucella melitensis strains in Peru remained susceptible to key antibiotics between 2000 and 2006.
  • Antimicrobial resistance does not appear to be a major factor contributing to brucellosis relapses in this population.
  • Continued surveillance of antimicrobial susceptibility is important for effective brucellosis management in Peru.